Clinical trial · Interventional
Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in ER-positive Breast Cancer
A Phase 2, Open-label, Non-randomized, Single Center Study to Explore Diagnostic Performance of [18F]Fluoroestradiol (FES) Positron Emission Tomography/Computed Tomography for the Assessment of Axillary Lymph Node Metastasis in Estrogen-positive Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to explore the diagnostic performance of \[18F\]FES PET/CT for the evaluation of axillary lymph node metastasis in patients with ER-positive breast cancer having clinically suspected or confirmed axillary lymph node metastasis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Invasive | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fluoroestradiol (18F) | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- [18F]FES PET/CT
- interventionNames
- Diagnostic Test: Fluoroestradiol (18F)
Primary outcomes (1)
- measure
- Patient based sensitivity and specificity of qualitative [18F]FES PET/CT evaluation for axillary lymph node metastasis
- timeFrame
- 80-100 minutes
- description
- diagnostic accuracy of qualitative \[18F\]FES PET/CT analysis
Secondary outcomes (4)
- measure
- Patient based sensitivity and specificity of qualitative [18F]FES PET/CT evaluation for pN2/3 axillary lymph node metastasis
- timeFrame
- 80-100 minutes
- description
- diagnostic accuracy of qualitative \[18F\]FES PET/CT analysis of pN2/3 axillary LN metastasis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female subjects aged 19 years or older regardless of race/ethnicity. * Subjects with histologically confirmed moderate-to-strong estrogen receptor-positive invasive breast cancer within 90 days prior to \[18F\]FES PET/CT imaging * Subjects whose primary tumor of cT1-3 according to the American Joint Committee on Cancer (AJCC) 8th tumor staging system * Subjects with suspected or confirmed axillary lymph node metastasis clinically or in imaging test (ultrasound) * Subjects who scheduled to undergo sentinel node biopsy or axillary lymph node dissection within 90 days of \[18F\]FES PET/CT imaging * Subjects whose Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2 points or less Exclusion Criteria: * Subject or the subject's legally acceptable representative does not provide written informed consent form * Subjects with confirmed or suspected distant metastases. * Previous history of ipsilateral axillary lymph node dissection, sentinel lymph node surgery, or lymph node dissection biopsy. * Patients who are scheduled for or have undergone chemotherapy, radiotherapy, antihormone therapy, targeted therapy, or immunotherapy between \[18F\]FES PET/CT and pathological diagnosis * Subjects who are pregnant or lactating. Exclusion of the possibility of pregnancy is made by one of the following: 1) Physiologically menopausal (menstruation has stopped for more than 2 years), 2) Surgically infertility (with a history of bilateral oophorectomy or hysterectomy), 3) In the case of subjects with a possibility of pregnancy, negative serum or urine pregnancy test before administration of \[18F\]FES has to be negative within 24 hours, and the subjects are instructed to use contraception during her participation in this study. * Subject has concurrent severe and/or uncontrolled and/or unstable medical condition other than cancer (e.g., congestive heart failure, acute myocardial infarction, severe lung disease, chronic kidney disease or chronic liver disease). * Subject is a relative or student of the investigator or otherwise in a dependent relationship * Subject has already participated in this study * Subject not being able to provide intact data for this study due to personal circumstances or other reasons in the judgment of the investigator
References
Publications (0)
Data not yet available